Paracor Medical
Founded Year
1999Stage
Dead | DeadTotal Raised
$91.9MAbout Paracor Medical
PARACOR MEDICAL, INC. was founded in 1999 to pursue the development of a family of devices intended to treat heart failure in new ways. Paracor is staffed with experienced engineers developing a device intended to be implanted, without requiring the patient to undergo the effects of open chest surgery. The 'HeartNet' device is a mesh support system to attenuate the impact of congestive heart failure. The company's ventricular support mesh, created out of nitinol, is designed to conform to the shape of the heart and provide elastic reinforcement to decrease stress in the heart muscle.
Paracor Medical Patents
Paracor Medical has filed 8 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
9/23/2009 | 6/5/2012 | Cardiac anatomy, Medical equipment, Circulating currencies, Automotive body parts | Grant |
Application Date | 9/23/2009 |
---|---|
Grant Date | 6/5/2012 |
Title | |
Related Topics | Cardiac anatomy, Medical equipment, Circulating currencies, Automotive body parts |
Status | Grant |
Paracor Medical Frequently Asked Questions (FAQ)
When was Paracor Medical founded?
Paracor Medical was founded in 1999.
Where is Paracor Medical's headquarters?
Paracor Medical's headquarters is located at 225 Humboldt Court, Sunnyvale.
What is Paracor Medical's latest funding round?
Paracor Medical's latest funding round is Dead.
How much did Paracor Medical raise?
Paracor Medical raised a total of $91.9M.
Who are the investors of Paracor Medical?
Investors of Paracor Medical include Delphi Ventures, RWI Ventures, Saratoga Ventures, InterWest Partners, De Novo Ventures and 8 more.
Who are Paracor Medical's competitors?
Competitors of Paracor Medical include NeoChord, Spectrum Medical, Respicardia, OtoKinetics, MiCardia and 16 more.
Compare Paracor Medical to Competitors
Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure
CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.
CardioMetrix is a medical device company developing implantable technologies to assist physicians in managing patients suffering from congestive heart failure (CHF).
Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.

Mitralign develops a catheter-based technology for percutaneous treatment of functional mitral regurgitation. It emulates surgical annuloplasty delivering a series of surgical implants directly into the mitral annulus by means of a catheter. The company was founded in 2004 and is based in Tewksbury, Massachusetts.

Cardiac Dimensions develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. Its initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. The company was founded in 2000 and is based in Kirkland, Washington.